ClinicalTrials.gg
CompletedNCT01264497Updated Dec 21, 2010

Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes

A Phase 2 interventional study of TH9507 in Type 2 Diabetes, sponsored by Theratechnologies. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2010-12-21.

Sponsored by Theratechnologies · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.

02

Conditions studied

  • Type 2 Diabetes
03

In context

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 55 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Theratechnologies is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or or surgically sterilized female subjects, 50 years of age or older;
  • Documented diagnosis of type 2 diabetes as defined by the American Diabetes Association;
  • Diagnosis of type 2 diabetes for at least 3 months before screening;
  • Subjects on stable diabetes treatment regimens (receiving oral hypoglycemics with or without insulin) for at least 2 months before screening;
  • Screening and pre-randomization glycosylated () \<10.0%, according to central laboratory;
  • (BMI) between 25 and 38 kg/m2
  • Subjects willing to perform specified home blood glucose monitoring and comply with all study protocol requirements;
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Serum creatinine >2 mg/dL;
  • Fasting triglycerides >1000 mg/dL;
  • Albuminuria >200 mg/24 hours;
  • Positive mammography (if female) or prostate-specific antigen (PSA) or prostate examination for cancer (if male);
  • Use of oral or parenteral in the 30 days before screening;
  • Use of any experimental or marketed growth hormone, growth hormone secretagogues, insulin-like growth factor-1 (IGF-1), or insulin-like growth factor binding protein-3 (IGFBP-3) during the previous 6 months;
  • Subjects with two or more severe hypoglycemia episodes within the past 6 months, or any hospitalization or emergency room visit due to poor glycemic control within the past 6 months. Similarly, during the lead-in period, any subject with more than one severe hypoglycemic episode or any hospitalization or emergency room visit due to poor glycemic control will be excluded from randomization;
  • History of or presence of active concomitant conditions or diseases (e.g., myocardial infarction, poorly controlled hypertension, thyroid disease, rheumatoid arthritis, seizure disorder, diabetic neuropathy, diabetic retinopathy [except subjects with only microaneurysms on fundus examination]) that would interfere with the protocol conduct and endpoint measurements;
  • Subjects with a major surgical operation during the 30 days before screening;
  • Subjects with known hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma;
  • Current cancer or history of cancer, except non-melanomatous skin cancer;
  • Subjects with active infection at any body site or a history of severe infection (requiring oral or parenteral treatment) during the 30 days before screening;
  • Subjects with abnormalities on screening laboratory evaluation (unless discussed with and approved by the medical monitor);
  • Subjects with allergy to synthetic growth hormone products or their ;
  • Subjects who had previously received growth hormones in any clinical trial;
  • Participation in a trial of an experimental drug or device within 90 days before screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Interventions

  • DrugTH9507

    1 and 2 mg, sc daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in relative insulin response

Secondary outcomes

  1. Change from baseline in glycosylated hemoglobin (HbA1c)

  2. Change in mean daily serum glucose concentrations

    Home blood glucose will be obtained four times per day (before breakfast, lunch, and dinner, and at bedtime) using a standard blood glucose meter

  3. Changes in the number of dose adjustments per week for insulin and/or oral hypoglycemic agents

  4. Number of subjects with a change in the control of diabetes

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. eCollection 2017. PubMed 28617838 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2002, a primary completion of Nov 2002 and a completion of Nov 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2010
First posted
Dec 21, 2010
Start
Feb 2002
Primary completionActual
Nov 2002
CompletionActual
Nov 2002
Last update
Dec 21, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01264497
Lead sponsor
Theratechnologies
First posted
Dec 21, 2010
Start date
Feb 2002
Primary completion
Nov 2002
Completion
Nov 2002
Last update
Dec 21, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tesamorelin

Start the discussion